{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-018454","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.940191+00:00","generated_at":"2026-05-17T03:23:47.840005+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Evofem extends Adjuvant convertible note maturity to April 2026; prepayment restricted","bullets":["Notes become due on earliest of: 6 months after Oct 13, 2025 (April 13, 2026), change of control, or acceleration.","No prepayment permitted before April 13, 2026 without Adjuvant's written consent.","Amendment dated October 13, 2025 modifies the October 2020 Securities Purchase Agreement.","Adjuvant Global Health Technology Fund holds the convertible promissory notes covered by the amendment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-018454","json":"https://secwatch.observer/filing/0001493152-25-018454.json","markdown":"https://secwatch.observer/filing/0001493152-25-018454.md","text":"https://secwatch.observer/filing/0001493152-25-018454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/0001493152-25-018454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315225018454/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:23:47.840005+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}